EGFRvIII peptide

EGFRvIII peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

H-LEEKKGNYV-OH

H-Leu-Glu-Glu-Lys-Lys-Gly-Asn-Tyr-Val-OH

9

95.28%

C₄₈H₇₈N₁₂O₁₆

1079.2

Synthetic

Powder

EGFRvIII peptide is a peptide derived from the fusion junction of epidermal growth factor receptor variant III (EGFRvIII), a variant of EGFR with amino acids 6–273 deleted. This spontaneously occurring alteration is found in a high percentage of primary human brain, breast, lung and ovarian tumours making EGFRvIII an ideal target of immunotherapy in EGFRvIII-expressing tumours. EGFRvIII peptide was identified from a number of candidates as the most immunogenic epitope for major histocompatibility complex I (MHC I) binding to induce tumour specific immune responses. In a glioblastoma mouse brain tumour model EGFRvIII peptide co-administered with the toll-like receptor 5 (TLR5) adjuvant Flagellin B induces an increase in CD8 + T cells and a decrease in Treg cells, inducing tumour apoptosis, inhibiting tumour growth and increasing survival.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• Moscatello et al (1997) A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res. 57(8) 1419 PMID: 9108438
• Wu et al (2006) Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas. J Neurooncol. 76(1) 23 PMID: 16155724
• Choi et al (2022) Flagellin synergistically enhances anti-tumor effect of EGFRvIII peptide in a glioblastoma-bearing mouse brain tumor model. BMC Cancer 22(1) 986 PMID: 36109710

Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.

Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.

Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.

In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.